-- Presentation to be webcast on www.exelixis.com --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 4, 2016-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the Leerink Partners Global Healthcare Conference taking place February 10-11 in New York, New York. The Exelixis presentation is scheduled for 11:05 AM EST/8:05 AM PST on Wednesday, February 10, 2016.

The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be require to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, COTELLIC™ (cobimetinib), a selective inhibitor of MEK, has been approved in Switzerland, the United States, and the European Union, and is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company’s website at www.exelixis.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160204006558/en/

Source: Exelixis, Inc.

Investors Contact:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and Corporate Communications
shubbard@exelixis.com
Media Contact:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com